Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB dualCAR-NK19/70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
NCT05667155Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CB dualCAR-NK19/70 in B-cell non-Hodgkin lymphoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of Dose Limiting Toxicity at 28 days. Started Dec 2022; status: recruiting.
02
Drugs
CB dualCAR-NK19/70
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05667155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667155.